MedPath

A Clinical Trial Into the Efficacy of rTMS Treatment for Treating Anorexia Nervosa and Bulimia Nervosa

Not Applicable
Withdrawn
Conditions
Anorexia Nervosa
Bulimia Nervosa
Eating Disorders
Registration Number
NCT04061304
Lead Sponsor
University of Manitoba
Brief Summary

This is a pilot study to test the efficacy of repetitive transcranial magnetic stimulation (rTMS) in treating individuals with Anorexia Nervosa and Bulimia Nervosa. The main objective of this study is to determine the short and long-term efficacy of repetitive transcranial magnetic stimulation (rTMS) in reducing eating disorder symptoms (i.e. binging, purging, restricting, intense fear of gaining wait, etc;) in Anorexia Nervosa and Bulimia Nervosa.

The investigators will also be comparing the brain activity patterns of individuals with Anorexia Nervosa and Bulimia Nervosa to healthy controls using electroencephalography (EEG). Further, the investigators would like to examine if the activation patterns in these patients change after receiving rTMS.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Confirmed diagnosis of Anorexia Nervosa or Bulimia Nervosa, must pass rTMS screening questionnaire
Exclusion Criteria
  • Diagnosis of another psychiatric disorder, except MDD.
  • Any rTMS counter-indications:
  • History of seizures
  • Metal in head
  • Currently pregnant
  • Having received rTMS for any reason in the past as this would interfere with participant blinding.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Weekly Binge/Purge Frequency on Eating Disorder Examinationbaseline, after week 1, week 2, and week 3 of treatment, 3 months post treatment, and 6 months post treatment.

Outcome measured by change of binge/purge episodes from baseline to the end of treatment. If the participant has a final score of 0 binges and 0 purges they will be considered in remission. A 50% improvement will be defined as a response to the rTMS.

Secondary Outcome Measures
NameTimeMethod
Change in Beck Anxiety Inventory (BAI)baseline, after week 1, week 2, and week 3 of treatment, 3 months post treatment, and 6 months post treatment.

Outcome range: 0-63, with higher scores reflecting higher levels of anxiety. A total of 21 questions are summed for a total score out of 63.

Change in Beck Depression Inventory (BDI)baseline, after week 1, week 2, and week 3 of treatment, 3 months post treatment, and 6 months post treatment.

Outcome range: 0-63, with higher scores reflecting higher levels of depression. A total of 21 questions are summed for a total score out of 63.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.